Quantitative RT-PCR analysis of 9 NSCLC cell lines previously characterized for sensitivity to the EGFR inhibitor gefitinib [21] and the FGFR inhibitor RO4383596 [11] confirmed the induction of FGFR2 and FGFR3 expression changes in a larger panel of NSCLC cells. The gene discussed is FGFR2; the disease is non-small cell lung carcinoma.